Stage IV breast cancer: treatment goals, subtypes and changing medicines

Make sure the current biology is understood

When feasible, a biopsy of a metastatic site can confirm the diagnosis and reassess ER, PR and HER2. Receptor findings can differ from the original breast tumor. Additional molecular testing may identify an option in selected situations.

The existing recurrence-biopsy guide covers that decision in detail. For treatment planning, gather both the original and current reports and ask which results are being used. If a biopsy is unsafe or unhelpful, ask how the team will choose treatment from the available information.

Sources and references: [1]

Agree on what treatment needs to achieve now

A person with few symptoms and slowly changing scans may have a different immediate priority from someone whose disease is threatening organ function. The team weighs the need for rapid control against toxicity and the opportunity to use a treatment over time.

Describe your daily activity, pain and the tasks you want to keep doing. Ask what benefit is expected over the first few months and what side effects might change the recommendation. These details help turn a list of options into a plan that fits your life.

Sources and references: [1]

For hormone receptor-positive disease

Endocrine treatment, often paired with a targeted agent such as a CDK4/6 inhibitor in an appropriate setting, is a central option for many HR-positive, HER2-negative cancers. Later choices may depend on molecular findings and previous therapy.

The presence of liver or lung metastases does not alone answer whether endocrine treatment is suitable. The urgency and degree of organ dysfunction matter. Ask whether the team sees an immediate need for a faster response and how that changes the comparison with chemotherapy or another approach.

Sources and references: [1] [2]

For HER2-positive disease

Anti-HER2 medicines are central to the treatment sequence. Options include antibodies, antibody-drug conjugates and selected targeted combinations. Previous exposure, the duration of response and brain involvement can influence the next regimen.

Bring a complete record of prior anti-HER2 medicines, even if they were given years earlier for early disease. Ask which health checks are needed, including heart monitoring when relevant, and how a new neurological symptom would be assessed.

Sources and references: [1] [3]

For triple-negative disease

Chemotherapy remains important, with immunotherapy relevant for selected patients based on the treatment setting and PD-L1 result. Germline BRCA findings can support a PARP inhibitor discussion in suitable cases. Antibody-drug conjugates may enter the sequence according to their indications and previous treatment.

Ask which tests would change the next choice. A broad promise of precision treatment is less useful than knowing whether the team is waiting for PD-L1, inherited genetic testing or another actionable result.

Sources and references: [1] [4] [5]

What counts as useful control

The team assesses scans, symptoms, organ function and treatment tolerance. Stable disease can be a useful result when you feel well and the treatment is manageable. Tumor markers, if followed, are interpreted with the other information.

Ask when scans are planned and what would trigger a change. A decision may follow clear progression, intolerable adverse effects or a new medical issue. Keep the treatment dates and best response documented so later choices can build on what has already worked.

Sources and references: [1]

Local treatment and symptom care still matter

Radiation or surgery may help with a specific problem such as painful bone disease, threatened structural damage or selected brain lesions. These procedures fit within the systemic plan. Pain management, rehabilitation and palliative care can support daily life during active cancer treatment.

New severe back pain with weakness, problems walking or changes in bladder or bowel control needs urgent assessment. Do not wait for the next routine scan. Ask the team which other symptoms require rapid contact based on the sites of your disease.

Sources and references: [1] [6]

Organizing a metastatic breast cancer review

Fudan University Shanghai Cancer Center has a breast cancer multidisciplinary service. For a review, prepare receptor results, scans and a timeline of every systemic treatment, including why each was stopped.

EastMedGo can help organize the inquiry around the unresolved question, such as the next treatment after progression or whether a new biopsy would change options. We can clarify consultation arrangements and coordination costs, and help identify the records the receiving team needs before a visit.

Sources and references: [7]

Common questions